ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 883

The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study

Jonathan Chan1, Anthony So2, Eric C. Sayre3 and J. Antonio Avina-Zubieta4, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Ankylosing spondylitis (AS) and thrombosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Venous thromboembolism (VTE)(pulmonary embolism [PE] and deep vein thrombosis[DVT]) is a potentially life threatening disease. Previous hospital-based studies have shown an increased risk of VTE in patients with ankylosing spondylitis (AS) but limited population-based data are available. We estimated the population-based risk of newly recorded PE and DVT among incident cases with AS compared with controls from the general population using physician-billing and hospitalization databases that cover the entire population of the province of British Columbia, Canada (~5 million)

Methods:

Our data includes all visits to health professionals and all hospital admissions from Jan 1, 1996 to Dec 31, 2012 and all dispensed medications from Sept 1, 1996 to Dec 31, 2012 for all individuals. We conducted a retrospective matched cohort study of all patients >18 years of age satisfying the following criteria: 1) two ICD-9 or 10 codes (720.0 or M45) for AS at least two months apart and within a 2-year period by any physician or hospitalization; 2) all AS cases had at least a 7-year run-in period before the 1st ICD code for AS in order to consider the case as incident. Each AS patient was matched with up to 10 controls by birth year, sex, and entry cohort time. We excluded cases that were diagnosed with other inflammatory conditions such as rheumatoid arthritis, vasculitis, myositis, and systemic lupus erythematosus on at least two visits. Ten non-AS controls matched by birth year, sex, and calendar year of follow-up were selected from the general population for each case.

Our outcomes were incident PE and DVT events that were recorded from outpatient visits, hospitalizations, or death certificates. For non-fatal events, we required the use of anticoagulation medications within six-months as part of all outcome definitions. We estimated relative risks (RRs) by comparing those with AS to age, sex, and entry time matched comparison cohorts, adjusting for potential known risk factors for VTE.

Results:

Among 7,190 incident cases of AS (51% male, mean age of 46yrs [SD 15.6]), 35, 47, and 69 developed PE, DVT, or both, respectively (incidence rates= 0.79, 1.06, and 1.56 per 1000 person years, respective) (see table). Compared with age, sex, and entry time matched controls, the RRs were 1.95 (95% CI; 1.36-2.81), 2.19 (95% CI; 1.60-3.00), and 2.06 (95% CI; 1.59-2.68) for PE, DVT, and both, respectively. After adjusting for covariates, the results remained similar (see table 1).

Conclusion:

This large population-based study indicates an increased risk of PE and DVT in patients with AS. Our results support the increased need for awareness and potential monitoring of these complications in AS patients.

Table 1. Relative Risk of Incident PE and DVT according to AS Status

AS

N=7,190

Non-AS

N=71,900

PE

Cases, N

7,165

35

71,775

177

Incidence Rate/1000 Person-Years

0.79

0.40

Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.95 (1.36, 2.81)

1.00

Glucocorticoid-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.60 (1.09, 2.34)

1.00

Number of Outpatient Visit-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.56 (1.08, 2.26)

1.00

*Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.36 (0.92, 1.99)

1.00

DVT

7,159

71,726

Cases, N

47

218

Incidence Rate/1000 Person-Years

1.06

0.50

Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

2.19 (1.60, 3.00)

1.00

Glucocorticoid-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

2.00 (1.44, 2.78)

1.00

Number of Outpatient Visit-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.71 (1.23, 2.36)

1.00

*Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.62 (1.16, 2.26)

1.00

VTE

7,143

71,638

Cases, N

69

336

Incidence Rate/1000 Person-Years

1.56

0.78

Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

2.06 (1.59, 2.68)

1.00

Glucocorticoid-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.83 (1.39, 2.40)

1.00

Number of Outpatient Visit-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.66 (1.27, 2.16)

1.00

*Fully-Adjusted Age-, Sex-, Entry Time-Matched Cox HR (95% CI)

1.53 (1.16. 2.01)

1.00

* Fully-adjusted models include the following selected covariates: Glucocorticoid use and number of outpatient visits.


Disclosure: J. Chan, None; A. So, None; E. C. Sayre, None; J. A. Avina-Zubieta, None.

To cite this abstract in AMA style:

Chan J, So A, Sayre EC, Avina-Zubieta JA. The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Ankylosing Spondylitis: A General Population-Based Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-risk-of-deep-venous-thrombosis-and-pulmonary-embolism-in-ankylosing-spondylitis-a-general-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-deep-venous-thrombosis-and-pulmonary-embolism-in-ankylosing-spondylitis-a-general-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology